Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

BACKGROUND: Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active...

Full description

Saved in:
Bibliographic Details
Published in:CNS Drugs
Main Authors: Ziemssen, Tjalf, Bass, Ann D., Berkovich, Regina, Comi, Giancarlo, Eichau, Sara, Hobart, Jeremy, Hunter, Samuel F, LaGanke, Christopher, Limmroth, Volker, Pelletier, Daniel, Pozzilli, Carlo, Schippling, Sven, Sousa, Livia, Traboulsee, Anthony, Uitdehaag, Bernard M. J., Van Wijmeersch, Bart, Choudhry, Zia, Daizadeh, Nadia, Singer, Barry A.
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2020
Subjects:
Original Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447657/
https://ncbi.nlm.nih.gov/pubmed/32710396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-020-00749-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items